Alicia Iruzun Lafitte
Principal @ M Ventures
Boston, United States
Alicia Iruzun Lafitte is a Series A investor at M Ventures in Boston focused on Therapeutics and Biotechnology. Alicia Irurzun-Lafitte joined UCB Ventures in March 2019 as Partner. Alicia joined from M Ventures, the corporate venture arm of Merck KGaA. Since 2014, she was instrumental in the closing of multiple new investments in Oncology, Immunology and Fertility areas in the US and Europe for the M Ventures Healthcare fund. Alicia was also closely involvedwith the built-up of Merck spin-offs. While at M Ventures, she served on the Board of Rewind Therapeutics as Director and Artios, iOnctura, Ribometrix, and TocopheRx as Observer.Prior to ventures, Alicia held roles in global business development at Merck Serono in Geneva and EMD Serono in Boston. During her time in business development she closed multiple early stage transactions and was involved in strategic corporate development initiatives.Alicia holds a MSc from Leiden University in Biopharmaceutical Sciences. She holds a Bachelor in Biomedical Sciences and completed her undergraduate studies between the University Claude Bernard Lyon 1 and Napier Edinburgh University.Alicia is based at the UCB Ventures' Boston office and she lives in New York.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Alicia Iruzun Lafitte invests in
Stages Alicia Iruzun Lafitte invests in
Countries Alicia Iruzun Lafitte invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Therapeutics 2 (50%)
- Biotechnology 2 (50%)
- Medical 1 (25%)
Stage
- Series A 2 (50%)
- Series B 1 (25%)
Country
- Belgium 1 (25%)
- United States 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Switch Therapeutics is a biotech company that develops RNAi therapies based on technology. The company was founded in 2020 and is based in San Francisco, California, United States. | $52M / Series A / Mar 14, 2023 | ||
| Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. | Series B / Jan 25, 2023 | ||
| Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. | $18.3M / Series A / Jan 04, 2018 | ||
| See all 4 investments → | |||
Co-Investors
About M Ventures
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
M Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christian Patze
Associate, Performance Materials
|
|||
Noga Yerushalmi
Head of Israel Bio-incubator
|
|||
Sarah Luppino
Associate
|
|||
Alexander Hoffmann
Principal
|
|||
|
Alicia Iruzun Lafitte
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alicia Iruzun Lafitte invest in?
Alicia Iruzun Lafitte invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alicia Iruzun Lafitte?
Public channels for Alicia Iruzun Lafitte include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alicia Iruzun Lafitte last invest?
The most recent investment recorded for Alicia Iruzun Lafitte closed in Mar 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
